The cost effectiveness of adalimumab (HUMIRA®) in UK patients with moderate to severe RA

被引：0
|
作者：
Bansback, NJ
Brennan, A
Sengupta, N
Pang, F
机构：
[1] Univ Sheffield, Sheffield, S Yorkshire, England
[2] Abbott Labs, Abbott Pk, IL 60064 USA
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2004年 / 63卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：512 / 513
页数：2
相关论文
共 50 条
  • [21] COST-EFFECTIVENESS OF GOLIMUMAB VERSUS INFLIXIMAB AND ADALIMUMAB FOR THE TREATMENT OF MODERATE TO SEVERE ULCERATIVE COLITIS
    Thorlund, K.
    Druyts, E.
    Eapen, S.
    Mills, E.
    VALUE IN HEALTH, 2014, 17 (03) : A38 - A38
  • [22] COST-EFFECTIVENESS OF TOFACITINIB COMPARED WITH ADALIMUMAB IN THE TREATMENT OF MODERATE TO SEVERE RHEUMATOID ARTHRITIS IN IRAN
    Rezaei, S.
    Taheri, S.
    Tahmasebi, N.
    Peiravian, F.
    Yousefi, N.
    VALUE IN HEALTH, 2018, 21 : S295 - S296
  • [23] Cost-Effectiveness of Golimumab Versus Infliximab and Adalimumab for the Treatment of Moderate to Severe Ulcerative Colitis
    Druyts, Kristian Thorlund Eric
    Kanters, Steve
    Eapen, Shawn
    Mills, Edward
    GASTROENTEROLOGY, 2014, 146 (05) : S202 - S202
  • [24] Sustained efficacy of adalimumab (HUMIRA™) plus methotrexate in rheumatoid arthritis (RA) patients.
    Schiff, MH
    Weisman, MH
    Furst, DE
    Kavanaugh, A
    Fischkoff, SA
    Spencer-Green, GT
    ARTHRITIS AND RHEUMATISM, 2003, 48 (09): : S314 - S315
  • [25] The cost effectiveness of adalimumab (HUMIRA®) vs. infliximab (REMICADE) in achieving clinical response at 1 and 3 years in patients with early rheumatoid arthritis (RA):: US analysis
    Davies, AS
    Hutton, J
    Cifaldi, MA
    Pang, F
    Spencer-Green, G
    ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 : 393 - +
  • [26] SUSTAINED EFFICACY OF ADALIMUMAB (HUMIRA®) PLUS METHOTREXATE (MTX) IN RHEUMATOID ARTHRITIS (RA) PATIENTS
    Schiff, M. H.
    Weisman, M.
    Furst, D. E.
    Kavanaugh, A.
    Spencer-Green, G.
    Segurado, O. G.
    RHEUMATOLOGY, 2004, 43 : 40 - 40
  • [27] Adalimumab (Humira®) dosing frequency in RA patient assistance programs
    McAndrews, MB
    Kosch, K
    Kern, C
    Holly, K
    Haas, JN
    ANNALS OF THE RHEUMATIC DISEASES, 2004, 63 : 265 - 266
  • [28] Efficacy of adalimumab (Humira®) in Canadian clinical practice:: Subanalysis of the canact trial for patients with moderate vs. severe rheumatoid arthritis
    Keystone, Edward C.
    Stewart, Jackie
    Cividino, Alfred
    Haraoui, Paul
    Guerette, Benoit
    JOURNAL OF RHEUMATOLOGY, 2007, 34 (07) : 1605 - 1605
  • [29] Effectiveness and safety of adalimumab in treating moderate to severe psoriasis patients with psoriatic arthritis in Taiwan
    Kao, Pei-Han
    Hui, Rosaline Chung-Yee
    Yang, Chih-Hsun
    Huang, Yu-Huei
    DERMATOLOGICA SINICA, 2015, 33 (03) : 119 - 123
  • [30] A RESOURCE UTILISATION STUDY COMPARING HUMIRA™ (ADALIMUMAB) WITH REMICADE® (INFLIXIMAB) FOR THE TREATMENT OF MODERATE TO SEVERE RHEUMATOID ARTHRITIS
    Hazleman, B.
    Ostor, A.
    Gurmin, V.
    Strickson, A.
    Pang, F.
    RHEUMATOLOGY, 2004, 43 : 79 - 79
12345